{
  "pmcid": "12009809",
  "sha256": "5de51984efccd2a940ce454b41314201110ff80883abaecebeb8277ebdeadc5a",
  "timestamp_utc": "2025-11-09T23:24:17.253846+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 13.57263157894737,
    "reading_ease": 23.157894736842138,
    "word_count": 271
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial on Hypertension Management in Aortic Coarctation Patients"
      },
      "Trial_Design": {
        "score": 2,
        "evidence": "Randomisation was performed using a computer-generated sequence, with allocation concealment ensured by sealed envelopes."
      },
      "Participants": {
        "score": 2,
        "evidence": "Participants were recruited from a tertiary care center, with eligibility criteria including a confirmed diagnosis of AoC and post-repair hypertension."
      },
      "Intervention": {
        "score": 2,
        "evidence": "Participants were randomised to receive either beta-blockers, ACE inhibitors, ARBs, or CCBs."
      },
      "Objective": {
        "score": 1,
        "evidence": "This randomised controlled trial aimed to evaluate the effectiveness of different antihypertensive strategies in AoC patients."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was the reduction in systolic blood pressure over a 12-month period."
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was performed using a computer-generated sequence, with allocation concealment ensured by sealed envelopes."
      },
      "Blinding": {
        "score": 1,
        "evidence": "Blinding was applied to outcome assessors."
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "A total of 200 participants were randomised: 50 to each treatment group, between January 2020 and June 2021."
      },
      "Number_Analysed": {
        "score": 2,
        "evidence": "Analysis was conducted on 196 participants using an intention-to-treat approach."
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "The mean reduction in systolic blood pressure was greatest in the ACE inhibitor group (mean difference = 5.2 mm Hg, 95% CI 3.1 to 7.3; p = 0.01)."
      },
      "Harms": {
        "score": 1,
        "evidence": "Adverse events were reported in 3% of the ACE inhibitor group and 1% of the beta-blocker group, with mild gastrointestinal side-effects."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "The trial was registered under number NCT12345678"
      },
      "Funding": {
        "score": 1,
        "evidence": "funded by the National Heart Institute."
      }
    },
    "total_score": 23,
    "max_score": 25
  }
}